Abstract Library

#4469 Therapeutic strategy for pancreatic neuroendocrine tumours: An overview of the TNE West Network (2016-2024)

Introduction: Neuroendocrine tumours (NETs) are relatively rare and often diagnosed at an advanced stage, typically occurring between the ages of 40 and 60. They primarily manifest in the gastrointestinal system, pancreas, bronchi, lungs, thymus, and thyroid.

Conference:

Presenting Author: Bengueddach A

Authors: Bengueddache A, Kehili H, Tidjane A, Tabeti B, Manouni C,

Keywords: neuroendocrine tumour, metastasis, somatostatin analogue, pancreas,

#4460 Digestive neuroendocrine tumours G1 and G2: Experience of the medical oncology department at the Oran University Hospital Establishment 1st November 1954

Introduction: The histological classification of neuroendocrine tumours (NETs) remains complex, and their grading is a major prognostic factor, essential for guiding appropriate management. Moreover, NETs raise unresolved histogenetic questions. The treatment of grade 1 (G1) NETs primarily relies on somatostatin analogues, while grade 2 (G2) NETs, being more heterogeneous, may require management that includes chemotherapy or targeted therapy.

Conference:

Presenting Author:

Authors: Kehili H, Bengueddache A, Boumansour N, Larbi Bounsbia L, Bechikh A,

Keywords: Digestive Neuroendocrine Tumour, Grade 1, Grade 2, Somatostatin Analogue,

#3773 Pancreatic neuroendocrine tumors in Oran – Epidemiological, histological and therapeutic aspects

Introduction: Pancreatic neuroendocrine tumors (pNET) are rare, they represent third of digestive NETs. Their incidence is increasing with a rate that has been multiplied by 5 over the past 20 years to reach 0.6 cases/100,000. This increase is probably related to better detection of this type of tumor. The discovery is often fortuitous or following a non-specific symptomatology which depends on the seat of the tumor. They are often the cause of mainly hepatic metastases. Only surgery at an early stage allows a good evolution. Few data are available on pNETs in our country.

Conference:

Presenting Author:

Authors: Boumansour N, Khalifa S, Kehili H, Bengueddache A, Tabeti B,

Keywords: pancreas, neuroendocrine tumor, epidemiology, histology,

#3771 Epidemiological profile and survival of neuroendocrine tumors of the ampulla of Vater

Introduction: Duodenal neuroendocrine tumors are rare, they represent nearly 2% of digestive NETs. Their incidence is increasing due to better detection. The diagnosis is often late because of the non-specific symptomatology of the tumor. The 5-year survival of duodenal NETs is 68% when the tumor is diagnosed at an early stage.

Conference:

Presenting Author:

Authors: Boumansour N, Saidi M, Khalifa S, Kehili H, Bengueddache A,

Keywords: Vater ampulla, neuroendocrine tumor, Epidemiology, Survival,

#3769 Adrenal neuroendocrine tumors in Oran – Epidemiology and survival

Introduction: Pheochromocytomas (PCC) are rare neuroendocrine tumors with a prevalence of 1/10000 in the general population. They are sporadic in 80% of cases, family forms are found in 10 to 20% of cases. PCCs represent 60% of multiple endocrine neoplasia type 2. They occur at any age with a peak between 30 and 50 years old. The clinical symptomatology dominated by arterial hypertension is linked to the hypersecretion of catecholamines. Metastases are common in the liver, bone or lung. The 5-year survival of malignant pheochromocytomas is less than 50%.

Conference:

Presenting Author:

Authors: Boumansour N, Khalifa S, Kehili H, Bengueddache A,

Keywords: adrenals, Neuroendocrine tumor, Pheochromocytoma, epidemiology, survival,